Advertisement

SLT-Particles for Two-Step Targeting in Boron Neutron Capture Therapy

  • E. Bohl
  • J. Carlsson
  • K. Edwards
  • S. Sjöberg
  • L. Gedda

Abstract

There are investigations proposing that liposomes, both stabilized and unstabilized, gather at sites of pathology, such as tumors, infections, and inflammations.1, 2, 3, 4 The site-specific uptake of liposomal substances ought to increase with a targeting agent on the liposome. One way to conduct the targeting is to use PEG (polyethylene glycol) as a spacer and conjugate the targeting agent to the terminus of the polymer.5 This conjugated liposome can be named a SLT-particle (stabilized liposome with targeting ligand).

Keywords

Boron Concentration Boron Content Boron Neutron Capture Therapy Target Step Boron Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    K. Shelly, D.A. Feakes, M.F. Hawthorne, P.G. Schmidt, T.A. Krisch, and W.F. Bauer. Model studies directed toward the boron neutron-capture therapy of cancer: Boron delivery to murine tumors with liposomes. Proc. Natl. Acad. Sci. USA, 89:9039–9043, 1992.PubMedCrossRefGoogle Scholar
  2. 2.
    D. Feakes, K. Shelly, and M.F. Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc. Natl. Acad. Sci. USA. 92:1367–1370, 1995.PubMedCrossRefGoogle Scholar
  3. 3.
    M.F. Hawthorne, and K. Shelly. Liposomes as drug delivery vehicles for boron agents. Journal of Neuro-Oncology. 33:53–58, 1997.PubMedCrossRefGoogle Scholar
  4. 4.
    M. Woodle. Sterically stabilized liposome therapeutics. Advanced Drug Delivery Reviews, 16:249–265.Google Scholar
  5. 5.
    T. Allen, E. Brandeis, C. Hansen, G. Kao, and S. Zalipsky. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochimia et Biophysica Acta. 1237:99–108, 1995.CrossRefGoogle Scholar
  6. 6.
    T. Hartman, and J. Carlsson. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiotherapy and Oncology. 31:61–75, 1993.CrossRefGoogle Scholar
  7. 7.
    H. Ghaneolhosseini. Boron Neutron Capture Therapy, Synthesis of Boronated Amines- and DNA Intercalating Agents for Potential Use in Cancer Therapy. Acta Universitatis Uppsaliensis, Comprehensive summaries of Uppsala Dissertations from the Faculty of Science and Technology, 356:62 pp. ISBN 91-554-4181-5, 1998.Google Scholar
  8. 8.
    L. Gedda. Boron Neutron Capture Therapy, Preclinical Studies of Compounds for Tumour Targeting. Acta Universitatis Uppsaliensis, Comprehensive Summaries of Dissertations from the Faculty of Medicine, 724:66 pp ISBN 91-554-4090-8. 1997.Google Scholar
  9. 9.
    P. Lindström, P. Olsson, J. Malmqvist, J. Pettersson, P. Lemmen, B. Werner, S. Sjöberg, Å. Olin, and J. Carlsson. New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-1 and B-Et-11-OMe in cultured human glioma and mouse melanoma cells. Anti-Cancer Drugs. 5:43–52, 1994.PubMedCrossRefGoogle Scholar
  10. 10.
    H. Nemoto, J. Cai, and N. Asao. Synthesis and biological properties of water-soluble p-boronophenyl alanine derivatives. Relationship between water solubility, cytotoxicity, and cellular uptake. J. Med. Chem. 38:1673–1678, 1995.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • E. Bohl
    • 1
  • J. Carlsson
    • 1
  • K. Edwards
    • 2
  • S. Sjöberg
    • 3
  • L. Gedda
    • 1
  1. 1.Biomedical Radiation SciencesRudbeck LaboratoryUppsalaSweden
  2. 2.Physical ChemistryUppsala UniversityUppsalaSweden
  3. 3.Organic ChemistryUppsala UniversityUppsalaSweden

Personalised recommendations